Enlivex Therapeutics (NASDAQ:ENLV) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Enlivex Therapeutics (NASDAQ:ENLV) from a sell rating to a hold rating in a research report released on Saturday.

Other equities analysts have also recently issued research reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Enlivex Therapeutics in a report on Monday, December 29th. HC Wainwright increased their price target on Enlivex Therapeutics from $7.00 to $13.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Finally, D. Boral Capital restated a “hold” rating on shares of Enlivex Therapeutics in a research report on Monday, November 24th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $13.00.

Enlivex Therapeutics Stock Performance

Shares of NASDAQ:ENLV opened at $1.16 on Friday. The stock has a market capitalization of $275.36 million, a price-to-earnings ratio of -2.11 and a beta of 1.55. Enlivex Therapeutics has a 1-year low of $0.66 and a 1-year high of $2.10. The company’s fifty day moving average is $0.99 and its two-hundred day moving average is $1.02.

Institutional Trading of Enlivex Therapeutics

Large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in Enlivex Therapeutics during the 4th quarter worth $33,000. Invesco Ltd. bought a new stake in shares of Enlivex Therapeutics during the fourth quarter valued at about $43,000. XTX Topco Ltd raised its stake in shares of Enlivex Therapeutics by 44.8% during the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock valued at $43,000 after purchasing an additional 19,132 shares in the last quarter. Jane Street Group LLC lifted its holdings in Enlivex Therapeutics by 244.1% in the fourth quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock worth $52,000 after purchasing an additional 52,553 shares during the period. Finally, HRT Financial LP grew its position in Enlivex Therapeutics by 719.4% in the 4th quarter. HRT Financial LP now owns 153,990 shares of the company’s stock valued at $108,000 after buying an additional 135,198 shares in the last quarter. 1.02% of the stock is currently owned by institutional investors and hedge funds.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.